Salvage craniospinal irradiation for recurrent intracranial germinoma: a single institution analysis. (5th January 2023)

• Record Type: Journal Article
• Authors: Kanamori, Masayuki; Shimoda, Yoshiteru; Umezawa, Rei; Iizuka, Osamu; Mugikura, Shunji; Suzuki, Kyoko; Ariga, Hisanori; Jingu, Keiichi; Saito, Ryuta; Sonoda, Yukihiko; Kumabe, Toshihiro; Tominaga, Teiji
• Is Part Of: Journal of radiation research. Volume 64:Number 2(2023)
• Page Start: 428
• Page End: 437
• Publication Date: 2023-01-05
• Subjects: recurrent intracranial germinoma -- radiation therapy -- salvage therapy -- long-term results; Radiology, Medical -- Periodicals; Radiobiology -- Periodicals; Radiation -- Periodicals; 616.0757
• DOI: 10.1093/jrr/rrac095
• Languages: English
• ISSNs: 0449-3060

Abstract

Abstract: This study investigated the effectiveness and safety of low-dose salvage craniospinal irradiation (CSI) for recurrent germinoma. We retrospectively reviewed long-term tumor control and late adverse effects in 15 recurrent germinoma patients treated at our hospital between 1983 and 2019. Following the first recurrence of germinoma, seven were treated with 24–30 Gy of salvage CSI, three underwent non-CSI, and five were treated with only chemotherapy. CSI achieved a significantly better recurrence-free survival rate after the first recurrence compared to other strategies (100% vs 33%, p < 0.001: log-rank test). To evaluate the safety of salvage CSI, we assessed the outcomes at the final follow-up of seven patients who received salvage CSI at first recurrence and three patients who received salvage CSI at second recurrence. The median follow-up period was 220 months after initial treatment. Five patients who received 40–50 Gy of radiation therapy or underwent multiple radiation therapy before salvage CSI were classified into Group A, whereas five patients treated with platinum-based chemotherapy and 24–32 Gy of radiation therapy to the primary site, whole ventricle, or whole brain were classified into Group B. In Group A, one had endocrine dysfunction and the other had visual dysfunction. None were socially independent. Meanwhile, in Group B, no endocrine or visual dysfunction was found, and three patients were socially independent. Salvage CSI achieved excellent tumor control in recurrent germinoma and was safe in patients initially treated with low-dose radiation therapy and chemotherapy.